German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Following the closing of the transaction, CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech.

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

COVID success story BioNTech (Nasdaq: BNTX) is to buy fellow German mRNA company CureVac (Nasdaq: CVAC). Shares in the latter ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...